Home>Topics>Stocks>Vanda Pharmaceuticals

Vanda Pharmaceuticals VNDA

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Vanda files patent infringement suit

      Headlines

      Mon, 16 Jun 2014

      In a regulatory filing , Vanda Pharmaceuticals ( VNDA ) discloses that it has filed a patent infringement suit against Roxanne Laboratories' ANDA for generic versions of iloperidone

    2. Midday Gainers / Losers

      Headlines

      Wed, 4 Jun 2014

      Top 10 Gainers: LSBI +39% . NQ +35% . THRD +31% . VNDA +24% . DRWI +22% . CLDN +21% . PL +18% . EGLE +13% . DRL +12% . HOTR +12% . Top 10 Losers: TSPT -34% . EBIX

    3. Investors like Hetlioz's potential in Europe

      Headlines

      Wed, 4 Jun 2014

      Shares of Vanda Pharmaceuticals ( VNDA +21.4% ) pop on increased volume in response to yesterday's announcement that the EMA accepted its MAA for Hetlioz. Post your comment!

    4. Premarket Gainers / Losers

      Headlines

      Wed, 4 Jun 2014

      Gainers: NQ +31% . PL +18% . DRWI +16% . VNDA +10% . SPWR +5% . Losers: FCEL -14% . TIBX -12% . JKS -8% . YGE -7% . TSL -6% . BLDP -5% . CSIQ -5% . Post your comment!

    5. EMA accepts Vanda's app for Hetlioz

      Headlines

      Tue, 3 Jun 2014

      The European Medicines Agency accepts Vanda Pharmaceuticals ' ( VNDA ) Marketing Authorization Application for Hetlioz ( tasimelteon ) for the treatment of non-24-hour sleep-wake disorder

    6. Encouraging Early Signs From Vanda's Hetlioz Launch Outweighed by Higher Cost Structure

      Commentary

      Fri, 9 May 2014

      Vanda Pharmaceuticals reported first-quarter results were below our expectations because of significantly higher-than-anticipated operating costs

    7. New Morningstar Analyst Report for Vanda Pharmaceuticals Inc

      Stock Reports

      Fri, 9 May 2014

      outstanding, which should help ensure that his interests are well aligned with those of other shareholders. Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its key

    8. Raising Vanda's Fair Value Estimate as Confidence in Tasimelteon's Launch Improves

      Commentary

      Tue, 30 Jul 2013

      We're raising our fair value estimate for Vanda VNDA to $10 per share, following the announcement that orphan sleep disorder drug tasimelteon has gained priority review designation

    9. Vanda shares jump as sleep disorder drug moves closer to market

      Headlines

      Tue, 30 Jul 2013

      (Reuters) - Shares of Vanda Pharmaceuticals Inc jumped nearly 42 percent on expectations that its sleep disorder drug could reach market earlier than expected after U.S. health regulators said it...

    10. Vanda Cuts Expenses in 1Q as it Prepares for New Drug Application Submission for Tasimelteon

      Commentary

      Thu, 9 May 2013

      Vanda VNDA reported first-quarter results that matched our expectations for continued stagnant Fanapt growth, countered by lowered operating

    « Prev12345Next »
    Content Partners